BioGaia subsidiary IBT takes rapid steps in development of a drug for premature infants
Infant Bacterial Therapeutics (IBT) aims to develop a unique orphan drug to prevent the fatal disease necrotising enterocolitis (NEC). The project has proceeded faster than previously scheduled and according to the updated development plan IBT expects to run two clinical trials within the next three years.
Please see enclosed pdf for full press release.
For additional information please contact
Peter Rothschild, President, BioGaia: 46 8 555 293 00
Staffan Strömberg, President IBT: 46 8 410 145 55
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com